(E)-5-Bromo-2-methoxy-4-((3-(methylthio)-5-phenyl-4H-1,2,4-triazol-4-ylimino)methyl)phenol, 5-Bromo-2-methoxy-4-[[[3-(methylthio)-5-phenyl-4H-1,2,4-triazol-4-yl]imino]methyl]phenol, GO 289, GO-289
GO289 is a highly potent and selective casein kinase CK2 (CKII) inhibitor (IC50 = 7 nM/CK2, 13 μM/PIM2, >50 μM/CLK2; <50% inhibition of CK1α/δ/γ and 56 other kinases at 5 μM) that targets CK2-specific residues (CK2α V66, M163, and H160) with more overall interactions at the CK2 ATP-binding pocket than TBB, DMAT & CX-4945. GO289 selectively inhibits cellular CK1 substrates phosphorylation (0.8-8 μM; HEK293T, U2OS), including clock proteins PER2, CRY1, CLOCK & BMAL1, and displays circadian period-lengthening (Bmal1-dLuc USOS EC50 = 3.3 μM) as well as growth inhibitory potency in CK2-dependent human renal cell carcinoma (RCC) cultures.
Potent and highly selective CK2 (CKII) inhibitor with circadian period-lengthening and cancer growth inhibitory efficacy in human renal cell carcinoma cultures.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.